Selecta Biosciences (NASDAQ:SELB – Get Rating) announced its quarterly earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09, Fidelity Earnings reports. Selecta Biosciences had a net margin of 24.85% and a return on equity of 21.22%. During the same quarter in the prior year, the firm earned ($0.04) EPS.
Selecta Biosciences Price Performance
Shares of NASDAQ SELB opened at $2.36 on Friday. The firm has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.44. The stock has a market capitalization of $358.27 million, a price-to-earnings ratio of 236.00 and a beta of 1.04. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of 0.45. Selecta Biosciences has a 52 week low of $0.65 and a 52 week high of $4.70.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on SELB. SVB Leerink initiated coverage on shares of Selecta Biosciences in a report on Monday, June 6th. They set an “outperform” rating and a $7.00 price target on the stock. StockNews.com downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, May 14th. TheStreet raised shares of Selecta Biosciences from a “d” rating to a “c-” rating in a report on Wednesday, May 25th. HC Wainwright decreased their price objective on shares of Selecta Biosciences from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 21st. Finally, Needham & Company LLC decreased their price objective on shares of Selecta Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 14th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.
Institutional Investors Weigh In On Selecta Biosciences
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mirabella Financial Services LLP acquired a new stake in Selecta Biosciences during the first quarter worth about $82,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Selecta Biosciences during the first quarter valued at about $33,000. Eqis Capital Management Inc. acquired a new stake in shares of Selecta Biosciences during the first quarter valued at about $30,000. State Street Corp increased its position in shares of Selecta Biosciences by 4.7% during the first quarter. State Street Corp now owns 1,790,985 shares of the company’s stock valued at $2,203,000 after acquiring an additional 80,662 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Selecta Biosciences by 213.0% during the first quarter. Renaissance Technologies LLC now owns 1,490,400 shares of the company’s stock valued at $1,833,000 after acquiring an additional 1,014,200 shares during the last quarter. 72.62% of the stock is currently owned by institutional investors and hedge funds.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.
- Get a free copy of the StockNews.com research report on Selecta Biosciences (SELB)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.